OraSure Tech Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/16/2026)
| Balance Sheet | Total Assets | 403,168,000.00 | ROE | 84.54 % |
| Balance Sheet | Total Equity | 340,827,000.00 | ROA | -17.05 % |
| Cashflow | Capital Expenditures | -4,197,000.00 | P/FCF | -5.12 |
| Cashflow | Free Cash Flow | -53,220,000.00 | – | – |
| Cashflow | Operating Cash Flow | -49,023,000.00 | P/CF | -5.56 |
| Income | Earnings per Share (diluted) | -0.94 | Div. Yield | – |
| Income | Net Income | -68,731,000.00 | P/E | -3.95 |
| Income | Shares Outstanding | 73,485,000.00 | P/B | 0.80 |
| Income | Total Revenue | 115,021,000.00 | P/S | 2.37 |
Ratios calculated on: 10/14/2026
Company Description
OraSure Technologies, Inc., is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using the Company´s oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. The Company´s diagnostic products include tests that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. The Company operates in two segments: OraSure business and DNAG. On August 17, 2011, the Company completed the acquisition of DNA Genotek Inc. (DNAG).
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.orasure.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more